Efficacy and safety of ibopamine in congestive heart failure

D. J. Van Veldhuisen*, A. R.J. Girbes, K. I. Lie

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The oral dopamine agonist, ibopamine, has beneficial cardiovascular, renal, and neuroendocrine effects. It is generally well tolerated by patient with congestive heart failure (CHF). Furthermore, the drug appears to be safe. Ibopamine may be used as an adjunct to therapy with digoxin, diuretics, and angiotensin-converting enzyme inhibitors for patients with advanced CHF, or as an alternative in those who do not tolerate these drugs. Research suggests that ibopamine may, be used as first-line therapy for early CHF, and it may be given to patients who are dopamine-dependent.

Original languageEnglish
Pages (from-to)21-26+52
JournalPrimary Cardiology
Volume20
Issue number12
Publication statusPublished - 1 Jan 1994

Cite this

Van Veldhuisen, D. J., Girbes, A. R. J., & Lie, K. I. (1994). Efficacy and safety of ibopamine in congestive heart failure. Primary Cardiology, 20(12), 21-26+52.